pemetrexed,cisplatin,gemcitabine,pembrolizumab
merck
['kn-671', 'nsclc', 'sclc', 'lcsm,(-blcsm)']
is neoadjuvant chemo-immunotherapy feasible for all your potentially operable stage ii-iii nsclc patients in the clinic? in kn-671 trial, only 796/1364 patients fulfil the eligibility criteria. that s 42% screening failure rate #asco23 #lcsm 
Medical Oncology 🏥 Hospital General Universitario Gregorio Marañón⎪@myESMO Faculty 🫁 ⎪Power to the patients #endlungcancer #lcsm